TLN1 and prostate carcinoma: Accumulating evidence suggests that the expression of Talin-1 is dysregulated in various malignant neoplasms, such as colorectal cancer [21], hepatocellular carcinoma [22], prostate cancer [16], and oral squamous cell carcinoma [23].